RxDoctor Payments Data

Nso Nso, MD

Hospitalist · Burr Evanston, ILNPI 1750898367

Payments from drug & device makers

What this record shows

The money is spread across several categories — grants (47.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Medtronic at 51.4% of the total. 2025 is the largest year on record at $5,324, more than ten times the $150 reported in 2022. Among hospitalist clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,476in general payments, 2019–2025

Across 88 payments — averaging $96.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Penumbra, Inc.$2K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$551
  • Novartis$337
  • Boehringer Ingelheim$292
  • Cook Medical LLC$201
  • plus $761 from 13 others

What the payments were for

  • Grants$4,00047%
  • Travel & lodging$1,40917%
  • Food & beverage$2,67132%
  • Education$3965%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,476 in reported general payments places this provider in the 95th percentile of 1,328 hospitalist providers in Illinois.

See all hospitalist providers in Illinois

Medicare billing

Part B allowed, 2024
$2,555
Medicare patients
16
Services billed
22

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan15$18,195
EliquisApixaban19$15,380
FarxigaDapagliflozin Propanediol13$7,570
Valsartan25$698
Atorvastatin Calcium43$612
Metoprolol Succinate27$478
Carvedilol14$286
Amlodipine Besylate17$159
Spironolactone20$153

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$337$18,19515 claims
PfizerEliquis$88$15,38019 claims
AstraZenecaFarxiga$19$7,57013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,328 hospitalist providers in Illinois.

Other hospitalist in Burr Evanston

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →